Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Judson, Ian; Verweij, Jaap; Gelderblom, Hans; Hartmann, Jörg T; Schöffski, Patrick; Blay, Jean-Yves; Kerst, J Martijn; Sufliarsky, Josef; Whelan, Jeremy; Hohenberger, Peter; Krarup-Hansen, Anders; Alcindor, Thierry; Marreaud, Sandrine; Litière, Saskia; Hermans, Catherine; Fisher, Cyril; Hogendoorn, Pancras CW; Dei Tos, A Paolo; van der Graaf, Winette TA; for the European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group,

doi:10.1016/S1470-2045(14)70063-4

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial

Author:

Judson, Ian

Verweij, Jaap ; Gelderblom, Hans ; Hartmann, Jörg T ; Schöffski, Patrick ; Blay, Jean-Yves ; Kerst, J Martijn ; Sufliarsky, Josef ; Whelan, Jeremy ; Hohenberger, Peter ; Krarup-Hansen, Anders ; Alcindor, Thierry ; Marreaud, Sandrine ; Litière, Saskia ; Hermans, Catherine ; Fisher, Cyril ; Hogendoorn, Pancras CW ; Dei Tos, A Paolo ; van der Graaf, Winette TA ; for the European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group,

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, COLONY-STIMULATING FACTOR, HIGH-DOSE DOXORUBICIN, EUROPEAN-ORGANIZATION, ADULT PATIENTS, DOUBLE-BLIND, OPEN-LABEL, II TRIAL, CHEMOTHERAPY, IMATINIB, TUMORS, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Disease Progression, Disease-Free Survival, Doxorubicin, Drug Administration Schedule, Europe, Female, Humans, Ifosfamide, Kaplan-Meier Estimate, Male, Middle Aged, Palliative Care, Patient Selection, Risk Factors, Sarcoma, Soft Tissue Neoplasms, Time Factors, Treatment Outcome, Tumor Burden, Young Adult, European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3211 Oncology and carcinogenesis

Abstract:

Effective targeted treatment is unavailable for most sarcomas and doxorubicin and ifosfamide-which have been used to treat soft-tissue sarcoma for more than 30 years-still have an important role. Whether doxorubicin alone or the combination of doxorubicin and ifosfamide should be used routinely is still controversial. We assessed whether dose intensification of doxorubicin with ifosfamide improves survival of patients with advanced soft-tissue sarcoma compared with doxorubicin alone.